Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Autolus Therapeutics plc

Get SEC filing alerts via email and in your feed for Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

About Autolus Therapeutics plc

Autolus Therapeutics plc is a biopharmaceutical company specializing in next-generation programmed T cell therapies for cancer and autoimmune diseases. Its core product, AUCATZYL (obe-cel), is an autologous CD19-targeting CAR T cell therapy approved for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Autolus develops modular, engineered T cell therapies designed to improve efficacy, safety, and durability, supported by proprietary manufacturing and global commercial capabilities targeting hematological and solid tumor markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Autolus Therapeutics plc

1
1
Autolus Therapeutics plc Autolus Therapeutics Reports 192% Revenue Growth to $26.2 Million, Net Loss of $71.6 Million

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Autolus Therapeutics plc Autolus Therapeutics Reports $74.3 Million in Product Revenue for 2025, Despite Increased Net Loss

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Autolus Therapeutics plc Autolus Therapeutics Reports $21.1M Revenue from AUCATZYL Launch in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Autolus Therapeutics plc Autolus Therapeutics Reports $20.9M Product Revenue in Q2 2025, Net Loss of $47.9M

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Autolus Therapeutics plc Autolus Therapeutics Reports $70.2 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Autolus Therapeutics plc Autolus Therapeutics Reports $220.6 Million Net Loss and $10.1 Million Revenue for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Autolus Therapeutics plc Autolus Therapeutics Reports Significant Financial Developments, Including Cash Increase and Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments